<DOC>
	<DOCNO>NCT00988832</DOCNO>
	<brief_summary>The aim study quantify infliximab therapy use UK consequent impact health care resource , help inform budget holder payer cost associate treatment Crohn 's Disease .</brief_summary>
	<brief_title>An Audit Patients With Crohn 's Disease Treated With Infliximab ( P06066 )</brief_title>
	<detailed_description>All interested hospital physician across UK prescribe infliximab part treatment Crohn 's Disease patient . include . It assume physician population consist primarily gastroenterologist , though general physician ( hospital-based ) interest Crohn 's Disease may also include .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis Crohn 's Disease . Over age 18 year . Must receive first infusion infliximab 1st January 2003 ( maintenance therapy license grant ) . Must receive least one infusion infliximab . A minimum 12 month data prior , 24 month data post infliximab exposure available medical record . Must care participate center entirety study period . Should involve clinical trial observational period ( ie , minimum 12 month 24 month first receive infliximab ) . Should receive biologic therapy prior infliximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>